Search research articles
Contact Us
Filters
Showing results (591-600 of 616) with videos related to
Page
of 62
Sort By:
The Canadian Journal of Cardiology
|
April 5, 2011
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary)
, Lawrence A Leiter, David H Fitchett, et al.
Lancet (London, England)
|
April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Javed Butler, Sanjiv J Shah, Mark C Petrie, et al.
The Canadian Journal of Cardiology
|
April 5, 2011
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group
, Lawrence A Leiter, David H Fitchett, et al.
The New England Journal of Medicine
|
August 28, 2018
Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery
C David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
Circulation
|
July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M Jackson, Pooja Dewan, Inder S Anand, et al.
The New England Journal of Medicine
|
April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
European Heart Journal
|
June 5, 2020
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Stefan D Anker, Javed Butler, Muhammad Shahzeb Khan, et al.
Circulation
|
November 6, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Kim A Connelly, C David Mazer, Pankaj Puar, et al.
Nature Medicine
|
December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Stefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
Lancet Regional Health. Americas
|
June 8, 2026
Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial
Ahmad Alli, C David Mazer, Fallon Dennis, et al.
Page
of 62
Search research articles
Search
Showing results (591-600 of 616) with videos related to
Sort By:
Page
of 62
The Canadian Journal of Cardiology
|
April 5, 2011
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary)
, Lawrence A Leiter, David H Fitchett, et al.
Lancet (London, England)
|
April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Javed Butler, Sanjiv J Shah, Mark C Petrie, et al.
The Canadian Journal of Cardiology
|
April 5, 2011
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group
, Lawrence A Leiter, David H Fitchett, et al.
The New England Journal of Medicine
|
August 28, 2018
Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery
C David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
Circulation
|
July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M Jackson, Pooja Dewan, Inder S Anand, et al.
The New England Journal of Medicine
|
April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
European Heart Journal
|
June 5, 2020
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Stefan D Anker, Javed Butler, Muhammad Shahzeb Khan, et al.
Circulation
|
November 6, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Kim A Connelly, C David Mazer, Pankaj Puar, et al.
Nature Medicine
|
December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Stefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
Lancet Regional Health. Americas
|
June 8, 2026
Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial
Ahmad Alli, C David Mazer, Fallon Dennis, et al.
Page
of 62